Outcomes of multiple sclerosis patients admitted with COVID-19 in a large veteran cohort.

ABSTRACT:

Background

Given concerns over immune function, the decision whether to continue disease modifying therapy (DMT) in multiple sclerosis (MS) patients during the COVID-19 pandemic has been challenging, complicated by the risk of MS disease progression in the absence of treatment.

Methods

This retrospective analysis of patients treated for COVID-19 infection at veteran affairs healthcare systems across the United States, investigated 30-day all-cause mortality after first positive COVID-19 in patients with and without MS. We examined mortality risk impact of disease modifying therapy for MS, accounting for other relevant factors known to be associated with COVID-19 mortality. Patients were propensity score matched in a 1:20 fashion based on MS diagnosis.

Results

49,737 C

SUBMITTER: Fuchs TA 

PROVIDER: S-EPMC9188116 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature